Combined Therapeutics (CTx) is a privately held biotechnology company developing the next generation of high-value mRNA vaccines to protect everyone, including vulnerable populations, from global infectious diseases as well as to treat cancer.
The company’s unique and proprietary mRNA platform, with an increased safety profile due to controlled biodistribution and high specificity, is built around Multi Organ Protective (MOPCTx) binding miRNA sequences combined with therapeutic mRNAs, allowing the targeting of therapeutic protein expression in specific tissues while reducing off-target effects to protect key vital organs such as the heart, liver, and kidneys.
The company’s initial focus is on developing vaccines and vaccine adjuvants for infectious diseases and oncology indications.
OUR TECHNOLOGY
Combined Therapeutics’ platform, MOPCTx, is comprised of a modified mRNA encapsulated in a lipid nanoparticle. The UTR region of the mRNA is modified to contain miRNA binding sequences. Due to the differential expression of miRNA in different cells and tissues in the body, our platform can be targeted to express the antigen preferentially at the site of injection while protecting key vital organs such as the heart, liver, and kidneys.
LATEST NEWS
September 10, 2025
September 15, 2025
September 19, 2025
Coronado, California